(HealthDay News) — Patients with multiple myeloma that relapses after BCMA-directed chimeric antigen receptor (CAR) T-cell therapy may benefit from salvage treatment with additional T cell-engaging therapies, according to a study published in Blood.
Researchers analyzed the salvage treatments and outcomes of 79 multiple myeloma patients whose disease progressed after treatment with BCMA-directed CAR T-cell therapy.
The patients received a median of 2 (range, 1-10) lines of salvage therapy. With the first salvage regimen, patients achieved an overall response rate of 43.4% and a median progression-free survival of 3.5 months.
In all, 35 patients (44.3%) received a T cell-engaging therapy after relapse, either a bispecific antibody or additional CAR T-cell therapy. The overall response rate for T cell-engaging therapies at any point after initial CAR-T relapse was 91.4%.
At a median follow-up of 21.3 months, the median overall survival was not reached in patients who received a T cell-engaging therapy after relapse. In the entire cohort, the median overall survival from the date of relapse was 17.9 months.
“Patients with multiple myeloma who relapse after BCMA-directed CAR-T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy,” the researchers concluded. “T cell-engaging therapies appear to maintain pronounced clinical activity in this setting.”
Several authors disclosed financial ties to the biopharmaceutical industry.